Login Register Cart 0
Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets

Editor-in-Chief

ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Effects of Sacubitril/Valsartan Versus Telmisartan in Type 2 Diabetic or Pre-Diabetic Patients with Hypertension and Without Heart Failure: The Rationale and Design of A Randomized Clinical Trial

Author(s): Ming-Tsung Sun, Tsung-Jui Wu, Yu-Kai Lin, Yen-Po Lin, Yun-Chen Chang and Gen-Min Lin*

Volume 22, Issue 1, 2022

Published on: 11 May, 2022

Page: [38 - 41] Pages: 4

DOI: 10.2174/1871529X22666220408223329

Price: $65

Abstract

Background: Sacubitril/valsartan has revealed superior glycemic and blood pressure control compared with enalapril and irbesartan in patients with heart failure and type 2 diabetes and in individuals with chronic kidney disease. However, whether the effects of sacubitril/valsartan remain the same in those without heart failure is unknown.

Methods: A multicenter randomized double-blinded trial will be carried out in five military hospitals in Taiwan for a period of 1 year. Participants with prior cardiovascular diseases and heart failure will be excluded. The purpose of the study is to compare the effects of sacubitril/valsartan (97/103 mg once or twice daily) on the temporal changes in fasting blood glucose, HbA1c, insulin resistance, and blood pressure levels with telmisartan (40 mg once or twice daily) in individuals with stage 1-3 hypertension and newly diagnosed type 2 diabetes or prediabetes who have an HbA1c ≥6.0% and a systolic blood pressure ≥130 mmHg or a diastolic blood pressure ≥85 mmHg. The inclusion criteria include the age of 35-70 years, women who are not pregnant, estimated glomerular filtration rate ≥45 ml/min per 1.73m2, and B-type natriuretic peptide levels <400 pg/ml.

Results: The sample size is estimated to be 502 participants for randomization according to an assumption of between-person standard deviation in systolic blood pressure of 15 mmHg or in HbA1c of 1.5%, which provides ≥80% power (at p =0.05) to detect a difference in systolic blood pressure of 4 mmHg or in HbA1c of 0.3% at the final follow-up. All participants will receive a comprehensive physical examination and tests for blood cell counts, blood biochemistry, urine analysis, 12-lead electrocardiography, and an echocardiography every 3 months.

Conclusion: All analyses will be performed based on the intention-to-treat principle among all randomized participants.

Keywords: Hypertension, sacubitril/valsartan, telmisartan, type 2 diabetes, prediabetes, heart failure.

« Previous Next »
[1]
McMurray, J.J.; Packer, M.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.L.; Shi, V.C.; Solomon, S.D.; Swedberg, K.; Zile, M.R. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med., 2014, 371(11), 993-1004.
[http://dx.doi.org/10.1056/NEJMoa1409077] [PMID: 25176015]
[2]
Zeliha, S.; Canan, A.E. General approaches to the stem cell therapy in diabetes mellitus as innovative researches. J Genet Mutat., 2018, 1(1), 4-5.
[3]
Vaskova, E.; Ikeda, G.; Tada, Y.; Wahlquist, C.; Mercola, M.; Yang, P.C. Sacubitril/valsartan improves cardiac function and decreases myocardial fibrosis via downregulation of exosomal mir-181a in a rodent chronic myocardial infarction model. J. Am. Heart Assoc., 2020, 9(13)e015640
[http://dx.doi.org/10.1161/JAHA.119.015640] [PMID: 32538237]
[4]
Abdel-Latif, G.A.; Elwahab, A.H.A.; Hasan, R.A.; ElMongy, N.F.; Ramzy, M.M.; Louka, M.L.; Schaalan, M.F. A novel protective role of sacubitril/valsartan in cyclophosphamide induced lung injury in rats: impact of miRNA-150-3p on NF-κB/MAPK signaling trajectories. Sci. Rep., 2020, 10(1), 13045.
[http://dx.doi.org/10.1038/s41598-020-69810-5] [PMID: 32747644]
[5]
Zhang, H.; Liu, G.; Zhou, W.; Zhang, W.; Wang, K.; Zhang, J. Neprilysin inhibitor-angiotensin ii receptor blocker combination therapy (sacubitril/valsartan) suppresses atherosclerotic plaque formation and inhibits inflammation in apolipoprotein E- deficient mice. Sci. Rep., 2019, 9(1), 6509.
[http://dx.doi.org/10.1038/s41598-019-42994-1] [PMID: 31019233]
[6]
Salmas, R.E.; Gulhan, M.F.; Durdagi, S.; Sahna, E.; Abdullah, H.I.; Selamoglu, Z. Effects of propolis, caffeic acid phenethyl ester, and pollen on renal injury in hypertensive rat: An experimental and theoretical approach. Cell Biochem. Funct., 2017, 35(6), 304-314.
[http://dx.doi.org/10.1002/cbf.3277] [PMID: 28833317]
[7]
Selamoglu, Z.S.; Ozdemir, I.; Ciftci, O.; Gulhan, M.F.; Savci, A. Antioxidant effect of ethanolic extract of propolis in liver of L-name treated rats. Adv. Clin. Exp. Med., 2015, 24(2), 227-232.
[http://dx.doi.org/10.17219/acem/40461] [PMID: 25931353]
[8]
Gogebakan, A.; Talas, Z.S.; Ozdemir, I.; Sahna, E. Role of propolis on tyrosine hydroxylase activity and blood pressure in nitric oxide synthase-inhibited hypertensive rats. Clin. Exp. Hypertens., 2012, 34(6), 424-428.
[http://dx.doi.org/10.3109/10641963.2012.665542] [PMID: 22471835]
[9]
Gülhan, M.F.; Özdemir, B.; Selamoğlu, Z.; Şahna, E. The effects of apitherapeutic agents on oxidative stress in serum metabolic parameters of hypertensive rats created by nitric oxide synthase inhibited. Sains Malays., 2021, 50(6), 1745-1754.
[http://dx.doi.org/10.17576/jsm-2021-5006-20]
[10]
Ozdemir, B.; Gulhan, M.F.; Sahna, E.; Selamoglu, Z. The investigation of antioxidant and anti-inflammatory potentials of apitherapeutic agents on heart tissues in nitric oxide synthase inhibited rats via Nω-nitro-L-arginine methyl ester. Clin. Exp. Hypertens., 2021, 43(1), 69-76.
[http://dx.doi.org/10.1080/10641963.2020.1806294] [PMID: 32799699]
[11]
Talas, Z.S.; Yurekli, M. The effects of enalapril maleate and cold stress exposure on tyrosine hydroxylase activity in some rat tissues. Cell Biochem. Funct., 2006, 24(6), 537-540.
[http://dx.doi.org/10.1002/cbf.1256] [PMID: 16149109]
[12]
Seferovic, J.P.; Claggett, B.; Seidelmann, S.B.; Seely, E.W.; Packer, M.; Zile, M.R.; Rouleau, J.L.; Swedberg, K.; Lefkowitz, M.; Shi, V.C.; Desai, A.S.; McMurray, J.J.V.; Solomon, S.D. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol., 2017, 5(5), 333-340.
[http://dx.doi.org/10.1016/S2213-8587(17)30087-6] [PMID: 28330649]
[13]
Birkenfeld, A.L.; Boschmann, M.; Moro, C.; Adams, F.; Heusser, K.; Franke, G.; Berlan, M.; Luft, F.C.; Lafontan, M.; Jordan, J. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J. Clin. Endocrinol. Metab., 2005, 90(6), 3622-3628.
[http://dx.doi.org/10.1210/jc.2004-1953] [PMID: 15741263]
[14]
Birkenfeld, A.L.; Budziarek, P.; Boschmann, M.; Moro, C.; Adams, F.; Franke, G.; Berlan, M.; Marques, M.A.; Sweep, F.C.; Luft, F.C.; Lafontan, M.; Jordan, J. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes, 2008, 57(12), 3199-3204.
[http://dx.doi.org/10.2337/db08-0649] [PMID: 18835931]
[15]
Coué, M.; Badin, P.M.; Vila, I.K.; Laurens, C.; Louche, K.; Marquès, M.A.; Bourlier, V.; Mouisel, E.; Tavernier, G.; Rustan, A.C.; Galgani, J.E.; Joanisse, D.R.; Smith, S.R.; Langin, D.; Moro, C. Defective natriuretic peptide receptor signaling in skeletal muscle links obesity to type 2 diabetes. Diabetes, 2015, 64(12), 4033-4045.
[http://dx.doi.org/10.2337/db15-0305] [PMID: 26253614]
[16]
Engeli, S.; Birkenfeld, A.L.; Badin, P.M.; Bourlier, V.; Louche, K.; Viguerie, N.; Thalamas, C.; Montastier, E.; Larrouy, D.; Harant, I.; de Glisezinski, I.; Lieske, S.; Reinke, J.; Beckmann, B.; Langin, D.; Jordan, J.; Moro, C. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J. Clin. Invest., 2012, 122(12), 4675-4679.
[http://dx.doi.org/10.1172/JCI64526] [PMID: 23114600]
[17]
Heinisch, B.B.; Vila, G.; Resl, M.; Riedl, M.; Dieplinger, B.; Mueller, T.; Luger, A.; Pacini, G.; Clodi, M. B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia, 2012, 55(5), 1400-1405.
[http://dx.doi.org/10.1007/s00125-011-2392-1] [PMID: 22159910]
[18]
Haynes, R.; Judge, P.K.; Staplin, N.; Herrington, W.G.; Storey, B.C.; Bethel, A.; Bowman, L.; Brunskill, N.; Cockwell, P.; Hill, M.; Kalra, P.A.; McMurray, J.J.V.; Taal, M.; Wheeler, D.C.; Landray, M.J.; Baigent, C. Effects of Sacubitril/Valsartan versus irbesartan in patients with chronic kidney disease. Circulation, 2018, 138(15), 1505-1514.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034818] [PMID: 30002098]
[19]
White, W.B. Comparative effects of telmisartan in the treatment of hypertension. J. Clin. Hypertens. (Greenwich), 2002, 4(4)(Suppl. 1), 20-25.
[PMID: 12147925]
[20]
Gosse, P. A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours. Vasc. Health Risk Manag., 2006, 2(3), 195-201.
[http://dx.doi.org/10.2147/vhrm.2006.2.3.195] [PMID: 17326326]

Rights & Permissions Print Cite
Article Metrics
29
© 2024 Bentham Science Publishers | Privacy Policy